Survivin and Its Variants in Breast Cancer
Author Information
Author(s): Ryan B, O'Donovan N, Browne B, O'Shea C, Crown J, Hill A D K, McDermott E, O'Higgins N, Duffy M J
Primary Institution: University College Dublin
Hypothesis
The study aims to compare the expression of survivin and its splice variants in different types of breast tissue.
Conclusion
The study found that survivin is predominantly expressed in breast cancer tissues compared to normal tissues, and its variants may have different roles in apoptosis.
Supporting Evidence
- Survivin was detected in 93.6% of primary breast carcinomas.
- Survivin-2B and survivin-ΔEx3 levels were significantly higher in nodal metastases than in primary carcinomas.
- Survivin mRNA levels correlated significantly with survivin protein levels.
Takeaway
This study looked at a protein called survivin in breast cancer and found that it is mostly present in cancer tissues, which might help us understand how cancer cells avoid dying.
Methodology
The study used semiquantitative RT–PCR to measure mRNA levels of survivin and its variants in various breast tissue samples.
Limitations
The study had a relatively small sample size for axillary nodal metastases and could not confirm the expression of a newly identified variant, survivin-3B.
Participant Demographics
The study included samples from primary breast carcinomas, axillary nodal metastases, fibroadenomas, and normal breast tissues.
Statistical Information
P-Value
p<0.0001 for survivin levels in carcinomas vs normal tissue
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website